This product innovatively combines neuronal in situ transdifferentiation technology with tumor immunotherapy for the treatment of glioblastoma, the most common and most malignant primary tumor of the CNS. It not only significantly enhances the cytotoxic killing of tumor cells, but also transdifferentiates chemoresistant, immunotherapy insensitive tumor stem cells or drug resistant escape variants into neuron like cells that have lost proliferative capacity. In doing so, it effectively eliminates the cellular source of tumor recurrence, addressing the key clinical challenge of high relapse rates in glioblastoma and markedly prolonging patient survival.
This is an innovative, broadly applicable therapy for retinal degenerative diseases (with indications including retinitis pigmentosa and age related macular degeneration, among others). Unlike conventional monogenic gene replacement therapies in ophthalmology, this product does not repair specific pathogenic mutations. Instead, it converts a class of retinal glial cells—Müller cells—into photoreceptors, thereby restoring or improving vision for patients with these blinding diseases.
At the same time, it alleviates fibrosis caused by glial proliferation, improves the microenvironment for photoreceptor survival, and protects remaining photoreceptors. Compared with mutation specific gene correction strategies, this approach serves a broader patient population, is effective in middle and late stage disease, and is more amenable to large scale industrialization.
In China alone, the patient populations for retinitis pigmentosa and age related macular degeneration are approximately 500,000 and 40 million, respectively. This product is expected to become a blockbuster drug with annual sales potential in the tens of billions of RMB.
The core of this technology is the use of viral vectors to deliver specific neuronal transcription factors into the brain, reprogramming large numbers of proliferative endogenous glial cells in damaged regions (such as the hippocampus or cortex) into functional neurons, thereby repairing injured neural circuits.
This technology holds the potential to reverse the course of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). Compared with traditional stem cell transplantation, it offers significant advantages, including absence of immune rejection, lack of tumorigenic risk, higher conversion efficiency, and lower cost.
